Form 4: TransMedics Group Director James R. Tobin Sells Shares Under 10b5-1 Trading Plan

Director James R. Tobin of TransMedics Group, Inc. sold shares of common stock on May 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• James R. Tobin, a director of TransMedics Group, Inc., reported the sale of common stock on May 1, 2024.
• The sales were executed under a Rule 10b5-1 trading plan established on November 21, 2023.
• A total of 13,033 shares were sold at prices ranging from $105.50 to $110.
• The shares were sold in multiple transactions at weighted average prices of $105.7, $106.89 and $108.47 and $110.
• Following the reported transactions, James R. Tobin directly owns 1,193 shares and indirectly owns 205,171 shares through the James R. Tobin 2012 Trust.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of stock sales by a company director under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment.

Risks

• The sale of shares by a director could be perceived negatively by investors, although it was conducted under a pre-arranged trading plan.

Industry Context

Insider trading activity is closely monitored by regulators and investors as it can provide insights into a company's performance and prospects. Rule 10b5-1 plans allow insiders to sell shares without being accused of trading on non-public information.

Stakeholder Impact

• The stock sale may have a minor impact on shareholder sentiment, but the existence of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates